Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).
详细描述
The purpose of this study is to identify the highest tolerated doses in drugs used to treat aggressive leukemia, lymphoma or multiple myeloma not responding to standard chemotherapy treatment. The drugs being used in this study include drugs frequently used in treating such diseases (mitoxantrone and etoposide) as well as a newer drug that has also been shown to be effective (topotecan).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients in the following disease categories will be considered eligible for this study:
- •Any acute leukemia beyond an initial attempt to induce a remission or after relapse
- •Chronic Myelogenous Leukemia in Blast Phase
- •Refractory Multiple Myeloma
- •Refractory non-Hodgkin's and Hodgkin's Lymphoma
- •Patients must be more than 14 days beyond prior myelotoxic chemotherapy
- •Several other eligibility criteria apply.
排除标准
- 未提供
研究组 & 干预措施
Arm 1
干预措施: Topotecan (Drug)
Arm 1
干预措施: Mitozantrone (Drug)
Arm 1
干预措施: Etoposide (Drug)